Skip to content

Artificial Intelligence-Assisted Community Eye Screening in Primary Healthcare: A Prospective Multicentre Diagnostic Accuracy and Implementation Study

Sep 2026 · F1000Research · 0 citations · 27 references
Retinal Imaging and Analysis

TL;DR

AI-assisted community eye screening showed high sensitivity and good overall diagnostic performance with strong operational feasibility and the false-positive burden, particularly among participants with diabetes, supports continued clinical oversight, image-quality assurance, and subgroup-specific validation before wider health-system adoption.

Abstract

Background Artificial intelligence (AI)-assisted retinal screening may extend access to eye care in primary healthcare, but prospective evidence on diagnostic performance and implementation under routine community conditions remains limited. Methods We conducted a prospective multicentre diagnostic accuracy and implementation study across 12 urban and rural community eye-screening centres in India from 1 January to 30 June 2025. Adults aged ≥18 years underwent AI-assisted retinal-image analysis followed by masked comprehensive ophthalmic examination. The primary outcome was participant-level diagnostic accuracy of the AI-generated referral classification for the composite reference-standard outcome of any referable ocular disease. Implementation outcomes included image-acquisition success, workflow completion, referral compliance, screening time, and questionnaire-based acceptance and satisfaction. Results Among 1,732 participants, 610 (35.2%) had referable ocular disease. The AI system produced 566 true-positive, 1,017 true-negative, 105 false-positive, and 44 false-negative classifications. Sensitivity was 92.8% (95% CI 90.4%–94.7%), specificity 90.6% (88.8%–92.3%), positive predictive value 84.4% (81.4%–87.0%), negative predictive value 95.9% (94.5%–97.0%), and overall accuracy 91.4% (90.0%–92.7%). The F1 score was 0.884, Cohen’s kappa was 0.816, and the AUC based on the three-level AI risk classification was 0.925 (bootstrap 95% CI 0.912–0.937). Image acquisition succeeded in 1,668 participants (96.3%), workflow completion was 98.7%, and referral compliance was 550/671 (82.0%). Mean community-acceptance, healthcare-provider-satisfaction, and participant-satisfaction scores were 4.56, 4.44, and 4.49, respectively. Conclusions AI-assisted community eye screening showed high sensitivity and good overall diagnostic performance with strong operational feasibility. The false-positive burden, particularly among participants with diabetes, supports continued clinical oversight, image-quality assurance, and subgroup-specific validation before wider health-system adoption.

Read PDF

Similar papers

Open access Sep 2026

Diabetic retinopathy screening using artificial intelligence: a comprehensive performance comparison on datasets from diverse populations and imaging modalities

The study highlights the impact of imaging equipment, demographics, and image quality on diagnostic performance and underscores the need for benchmarking AI-based DR screening tools using standardized datasets that encompass diverse populations and imaging conditions.

Philipp Schapotschnikow, Vladyslav Dusiak, Murat Osswald et al. · 0 citations
Open access Oct 2026

Cost-effectiveness of community-based artificial intelligence screening for retinopathy of prematurity

Background Retinopathy of prematurity (ROP) is one of the leading causes of childhood blindness globally, but particularly in middle-income countries, where neonatal survival has improved faster than access to specialist ophthalmic care. Although telemedicine and artificial intelligence (AI)-assisted screening show pro...

Jia-Yue Xu, Zhi-Han Zhang, Guan-Ran Zhang et al. · 0 citations
Review Open access Oct 2026

From validation to public health impact: implementing equitable AI-enabled diabetic retinopathy screening

Diabetic retinopathy (DR) remains a preventable cause of vision loss as diabetes prevalence rises worldwide. Artificial intelligence (AI)-enabled retinal screening has progressed from retrospective validation to prospective and real-world deployment, with recent reviews showing high diagnostic performance across fundus...

Jing Chen, Bin Chen · 0 citations
Open access Sep 2026

Performance Assessment of an Artificial Intelligence System Used for Case Detection in a Large Community-based Diabetic Retinopathy Screening Program: A Retrospective Diagnostic Accuracy Validation Study

Background. In the Philippines, Artificial Intelligence (AI) systems used for diabetic retinopathy (DR) screening are still an emerging technology. There are several AI and Deep Learning Systems (DLS) developed and licensed abroad that are currently undergoing FDA approval in the Philippines. The challenge is to valida...

Maria Kristina DG. Eduardo, Junn R. Pajarillo · 0 citations
Review Open access Aug 2026

Autonomous AI-driven point-of-care screening for diabetic retinopathy compared to reading center multi-expert clinical review: results from three prospective controlled pivotal validation studies with AEYE-DS in over 1,200 patients

Purpose Diabetic retinopathy (DR) remains the leading cause of blindness among working-age adults and requires regular screening to detect progression among the growing global diabetic population. This study evaluated the performance of AEYE-DS, an autonomous artificial intelligence (AI) system designed for high-throug...

Zack Dvey-Aharon, Moshe Livne, Danny Margalit et al. · 0 citations
Review Open access Aug 2026

Artificial Intelligence for Real-Time Any-Stage Diabetic Retinopathy Detection: Systematic Review and Meta-analysis

Introduction: Diabetic retinopathy (DR) is a leading cause of blindness among working-age adults worldwide. Traditional manual screening methods are often time-consuming and require specialized resources, limiting their accessibility. This review evaluates the diagnostic accuracy of artificial intelligence (AI)–assiste...

Annisa Safira Rifasanti, Hotma Lestari, Abid Nizar Zuhdi · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.